Mar 31 2011
Asuragen, Inc. announced today the launch of its new miRNA Biofluids service offering designed to interrogate miRNAs from serum, plasma, cerebral spinal fluid, and urine. Supported by a growing body of literature, the utility of miRNA biomarkers in biofluids has been demonstrated for numerous disease areas including Cancer, Neurology, Autoimmune, and Cardiovascular diseases. Over the past 5 years, Asuragen scientists have developed a suite of optimized protocols, now available as services, for the isolation and analysis of miRNAs from diverse biofluids. The ability to perform biomarker analysis from easily accessible and regenerative biofluid samples, in contrast to procuring invasive tissue biopsies, greatly facilitates sample collection and patient recruitment for clinical studies.
"We are excited to extend our proven track record of miRNA biomarker expertise to these accessible sample types that will enable our pharmaceutical partners to simplify and accelerate their work in drug development," said Carol Berry, Senior Vice President and General Manager of Asuragen's Genomic Services. "In 2010 we initiated an early access program to a selected number of pharmaceutical, biotechnology and academic partners that have worked with us to successfully profile over 1,000 unique biofluid samples amassing a wealth of data for our partners."
SOURCE Asuragen
Metabolic markers tied to increased risk of depression and anxiety, study finds